Edmond M. Kwan
A5089420153- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Molecular Biology Techniques and Applications
- Mass Spectrometry Techniques and Applications
- Hormonal and reproductive studies
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- Multiple Myeloma Research and Treatments
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Venous Thromboembolism Diagnosis and Management
- Bone health and treatments
- Lung Cancer Treatments and Mutations
- Case Reports on Hematomas
- RNA modifications and cancer
- BRCA gene mutations in cancer
- Sphingolipid Metabolism and Signaling
- Radiation Therapy and Dosimetry
- Brain Metastases and Treatment
Monash University
2018-2025
University of British Columbia
2021-2025
Eastern Health
2025
Monash Health
2017-2023
Peter MacCallum Cancer Centre
2017-2023
Monash Medical Centre
2020
Western Hospital
2020
The Royal Melbourne Hospital
2015-2017
Moorabbin Hospital
2016
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility risk stratification unclear. Here, we intersect ctDNA%, treatment outcomes, clinical characteristics across 738 plasma samples from 491 male mCRPC patients two randomized multicentre phase II trials a prospective province-wide blood biobanking program. ctDNA% correlates...
BackgroundMetastatic prostate cancer is a clonally heterogeneous disease state characterized by progressive somatic perturbations. The aim of this study was to identify cell free DNA- (cfDNA-) based alterations and their associations with outcomes in metastatic cancer.MethodsIn longitudinal prospective cohort plasma cfDNA/circulating tumor DNA (ctDNA) analyzed before, during, after androgen deprivation therapy (ADT) 4 independent patient groups ranging from untreated hormone sensitive...
Abstract Purpose: Androgen receptor pathway inhibitors (ARPI) are standard of care for treatment-naïve metastatic castration-resistant prostate cancer (mCRPC), but rapid resistance is common. Early identification will improve management strategies. We investigated whether changes in circulating tumor DNA (ctDNA) fraction during ARPI treatment linked with mCRPC clinical outcomes. Experimental Design: Plasma cell-free was collected from 81 patients at baseline and after 4 weeks first-line two...
[177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy has a favorable toxicity profile in patients with metastatic castration-resistant prostate cancer (mCRPC). Therapy-related myeloid neoplasm (t-MN) been described after [177Lu]Lu-DOTATATE but not, to our knowledge, yet reported [177Lu]Lu-PSMA. This case series describes 5 mCRPC who developed t-MN [177Lu]Lu-PSMA at institution. Methods: In this single-center retrospective analysis, we reviewed all treated Patients biopsy-proven during...
Abstract Background DNA originating from degenerate tumour cells can be detected in the circulation many types, where it used as a marker of disease burden well to monitor treatment response. Although circulating (ctDNA) measurement has prognostic/predictive value metastatic prostate cancer, its utility localised is unknown. Methods We performed whole-genome sequencing tumour-normal pairs eight patients with clinically undergoing prostatectomy, identifying high confidence genomic...
Abstract Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish significant resource of patient-derived xenografts (PDXs) prostate for rapid and systematic evaluation candidate therapies. The PDX collection comprises 59 tumors collected from 30 patients between 2012–2020, coinciding with availability abiraterone enzalutamide. PDXs represent the clinico-pathological genomic spectrum cancer, treatment-naïve primary castration-resistant metastases. Inter-...
CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 9KD, specifically evaluating rucaparib.
Genomic alterations in DNA damage response (DDR) genes are common metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic events impact prognosis and/or treatment is vital for optimising clinical outcomes.
<b>Background:</b><sup>177</sup>Lutetium PSMA-617 (Lu-PSMA-617) is an effective therapy for metastatic castrate-resistant prostate cancer (mCRPC). However, treatment resistance occurs frequently and combination therapies may improve outcomes. We report the final safety efficacy results of a phase I/II study combining Lu-PSMA-617 with idronoxil (NOX66), radiosensitiser, examined potential clinical, blood-based imaging biomarkers. <b>Methods:</b> 56 men progressive mCRPC previously treated...
Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 20-30% of men with metastatic castration-resistant prostate cancer (mCRPC). Ceramide metabolism may have a role ARSI resistance. Our study's aim is investigate the association ceramide-sphingosine-1-phosphate (ceramide-S1P) axis mCRPC.Lipidomic analysis (∼700 lipids) was performed on plasma collected from 132 mCRPC, before commencing enzalutamide or abiraterone. AR gene aberrations 77 these were identified by...
Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs plasma cell-free DNA (cfDNA) has proven to be challenging. With emerging data supporting Akt inhibition PTEN-deficient mCRPC, we profiled pathway aberrations patients with mCRPC using a novel cfDNA assay optimized for CNV detection.
Abstract Background Both changes in circulating lipids represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumour genetic aberrations are individually associated with worse clinical outcomes men metastatic castration-resistant prostate cancer (mCRPC). A key question is how the lipid environment genome interrelated order to exploit this therapeutically. We assessed association between (3LS), mCRPC. Methods performed plasma lipidomic analysis cell-free DNA (cfDNA)...